Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Tislelizumab × sintilimab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 45 Stomach Neoplasms 38 Carcinoma, Non-Small-Cell Lung 32 Colorectal Neoplasms 19 Esophageal Squamous Cell Carcinoma 16 Lung Neoplasms 10 Rectal Neoplasms 9 Nasopharyngeal Carcinoma 9 Esophageal Neoplasms 8 Pancreatic Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Cholangiocarcinoma 6 Neoplasms 5 Neoplasm Metastasis 5 Liver Neoplasms 4 Endometrial Neoplasms 4 Uterine Cervical Neoplasms 3 Triple Negative Breast Neoplasms 3 Recurrence 3 Lymphoma, Extranodal NK-T-Cell 3 Colorectal Cancer Metastatic 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Advanced Solid Tumors 3 Advanced Solid Tumor 3 Turcot syndrome 2 Thyroid Neoplasms 2 Solid Tumor 2 Small Cell Lung Carcinoma 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04906044 2023-11-18

STARS-RC03

The First Hospital of Jilin University

Phase 1 Active not recruiting

Gastrointestinal

Tislelizumab

Data powered by HemOnc (CC BY 4.0) Colophon ⚡